13D Filing: Viking Global and Axovant Sciences Ltd (AXON)

Page 5 of 19

Page 5 of 19 – SEC Filing

CUSIP No. G0750W104 13D Page 5 of 18 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Equities II LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

75,000,000

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

75,000,000

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

69.8%*

14

TYPE OF REPORTING PERSON

PN

* The calculation assumes that there are a total of 107,392,826 Common Shares outstanding
as of June 9, 2017, as reported by the Issuer on its Annual Report on Form 10-K for the fiscal year ended March 31, 2017, filed
with the SEC on June 13, 2017.

Follow Sio Gene Therapies Inc. (NASDAQ:SIOX)

Page 5 of 19